ES513964A0 - Procedimiento de obtencion de composiciones antiateroscleroticas. - Google Patents

Procedimiento de obtencion de composiciones antiateroscleroticas.

Info

Publication number
ES513964A0
ES513964A0 ES513964A ES513964A ES513964A0 ES 513964 A0 ES513964 A0 ES 513964A0 ES 513964 A ES513964 A ES 513964A ES 513964 A ES513964 A ES 513964A ES 513964 A0 ES513964 A0 ES 513964A0
Authority
ES
Spain
Prior art keywords
antiaterosclerotic
compositions
procedure
obtaining
obtaining antiaterosclerotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES513964A
Other languages
English (en)
Spanish (es)
Other versions
ES8305212A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ES8305212A1 publication Critical patent/ES8305212A1/es
Publication of ES513964A0 publication Critical patent/ES513964A0/es
Granted legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
ES513964A 1981-07-16 1982-07-14 Procedimiento de obtencion de composiciones antiateroscleroticas. Granted ES513964A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/283,852 US4407795A (en) 1981-07-16 1981-07-16 Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use

Publications (2)

Publication Number Publication Date
ES8305212A1 ES8305212A1 (es) 1983-04-16
ES513964A0 true ES513964A0 (es) 1983-04-16

Family

ID=23087838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513964A Granted ES513964A0 (es) 1981-07-16 1982-07-14 Procedimiento de obtencion de composiciones antiateroscleroticas.

Country Status (11)

Country Link
US (1) US4407795A (en])
EP (1) EP0070368A1 (en])
JP (1) JPS5818342A (en])
AU (1) AU8605082A (en])
DK (1) DK318982A (en])
ES (1) ES513964A0 (en])
GR (1) GR76175B (en])
IL (1) IL65818A0 (en])
PL (1) PL237497A1 (en])
PT (1) PT75254B (en])
ZA (1) ZA825069B (en])

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
HU190818B (en) * 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4732915A (en) * 1983-11-02 1988-03-22 Alza Corporation Process for increasing solubility of drug
JPS6140298A (ja) * 1984-06-30 1986-02-26 Zeria Shinyaku Kogyo Kk シクロアルテノ−ルフエルラ酸エステル−シクロデキストリン複合体
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5153166A (en) * 1988-08-18 1992-10-06 Trustees Of At Biochem Chromatographic stationary supports
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5942501A (en) * 1996-08-16 1999-08-24 Collaborative Laboratories, Inc. Cyclodextrin derivative complex
FR2823207B1 (fr) * 2001-04-10 2004-12-03 Pf Medicament Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
AU2014233018A1 (en) * 2013-03-15 2015-10-01 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472835A (en) * 1964-02-12 1969-10-14 American Mach & Foundry Schardinger dextrins
US3453257A (en) * 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3459732A (en) * 1967-03-22 1969-08-05 Corn Products Co Cyclodextrin carbamates
US3453260A (en) * 1967-03-22 1969-07-01 Corn Products Co Cyclic anhydride esters of cyclodextrin
US4066829A (en) * 1976-07-12 1978-01-03 American Cyanamid Company Malto-dextrin poly(H-)sulfates
US4100342A (en) * 1976-08-09 1978-07-11 Fmc Corporation Process of producing dextrin carboxylates
ZA784196B (en) * 1977-08-26 1979-07-25 American Cyanamid Co Method of treating atherosclerosis
EP0031603A1 (en) * 1979-12-31 1981-07-08 American Cyanamid Company Pharmaceutical composition of matter
US4311694A (en) * 1979-12-31 1982-01-19 American Cyanamid Company Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials

Also Published As

Publication number Publication date
AU8605082A (en) 1983-01-20
PT75254A (en) 1982-08-01
PL237497A1 (en) 1984-09-10
ES8305212A1 (es) 1983-04-16
PT75254B (en) 1984-07-23
ZA825069B (en) 1983-05-25
US4407795A (en) 1983-10-04
IL65818A0 (en) 1982-08-31
JPS5818342A (ja) 1983-02-02
GR76175B (en]) 1984-08-03
DK318982A (da) 1983-01-17
EP0070368A1 (en) 1983-01-26

Similar Documents

Publication Publication Date Title
ES513964A0 (es) Procedimiento de obtencion de composiciones antiateroscleroticas.
DE3280162D1 (de) Polyaethylenzusammensetzung.
ES516374A0 (es) Procedimiento para la obtencion de composiciones poliolefinicas.
FI821013L (fi) Kompositioner
ES509753A0 (es) Procedimiento de obtencion de quinazolinonas.
NO820795L (no) Fremgangsmaate for mikroinnkapsling.
ES513386A0 (es) Procedimiento de obtencion de composiciones oftalmologicas.
ES515084A0 (es) Procedimiento para la obtencion de 2-arilimidazopiridinas.
FI822630A0 (fi) Kompositioner
FI820518A7 (fi) Menetelmä substituoitujen 3-amino- sydnonimiinien valmistamiseksi.
FI822408A7 (fi) Menetelmä amidobentsamidien valmistamiseksi.
ES511765A0 (es) Procedimiento para la obtencion de composiciones de revestimiento.
ES515445A0 (es) Procedimiento para la obtencion de amino-organoaminosilosanos.
ES513387A0 (es) Procedimiento de obtencion de composiciones oftalmologicas.
ES516842A0 (es) Procedimiento para la obtencion de benzofuranonas.
ES518617A0 (es) Procedimiento para la obtencion de p-tercioctil-fenol.
ES522323A0 (es) Procedimiento para la obtencion de 2-halogenopropionatos sustituidos.
IT8122813A0 (it) Procedimento di preparazione di n-cicloesilbenzotiazol-2-solfenammi de.
RO85094A (ro) Procedeu pentru obtinerea de poliamide filabile
ES510963A0 (es) Procedimiento de preparacion de alcoxiaminohidridosilanos.
NO821826L (no) Fremgangsmaate for gjeninnsetting av anodespiss.
ES517428A0 (es) Procedimiento de preparacion de derivados bencilidenicos.
ES516880A0 (es) Procedimiento de preparar derivados de p-acilaminofenol.
ES521597A0 (es) Procedimiento de preparacion de compuestos piridotienopiridacinicos.
NO155443C (no) Fremgangsmaate til avvanning av torvstykker.